Evidence map›Paper›PMID 33488114›Full record

ArticleInternational journal of general medicine2021

Impact of PCSK9, WDR12, CDKN2A, and CXCL12 Polymorphisms in Jordanian Cardiovascular Patients on Warfarin Responsiveness and Sensitivity.

Rasheed K Ibdah, Laith N Al-Eitan, Nasr N Alrabadi, Ayah Y Almasri, Adan H Alnaamneh, Rame H Khasawneh, Mansour A Alghamdi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of general medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Personalized medicine in cardiovascular disease: review of literature.Journal of diabetes and metabolic disorders · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Rasheed K IbdahDivision of Cardiology, Department of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0001-7872-973X
Laith N Al-EitanDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0003-0064-0190
Nasr N AlrabadiDepartment of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.ORCID 0000-0002-5541-8362
Ayah Y AlmasriDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, Jordan.
Adan H AlnaamnehDepartment of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, Jordan.
Rame H KhasawnehDepartment of Hematopathology, King Hussein Medical Center (KHMC), Jordan Royal Medical Services (RMS), Amman, Jordan.ORCID 0000-0002-6716-2851
Mansour A AlghamdiDepartment of Anatomy, College of Medicine, King Khalid University, Abha, Saudi Arabia.ORCID 0000-0002-6613-1498
Jordan University of Science and Technology · JOKing Hussein Medical Center · JOKing Khalid University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe main objective of this study is sought to determine the impacts of PCSK9, WDR12, CDKN2A, and CXCL12 polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and stabilization phases of therapy.

methodsThis study took place at the anticoagulation clinic at Queen Alia Heart Institute (QAHI) in Jordan. DNA samples were collected from 212 cardiovascular patients and 213 healthy controls. Genomic SNPs genotyping was conducted using the MassARRAY System at the Australian Genome Research Facility.

resultsThis study assessed 10 polymorphisms (rs11206510 within the

conclusionCarriers of CXCL12 rs2862116 polymorphism had an increased risk to be warfarin extensive responders compared to those with no or only one polymorphism (P = 0.01). However, the presence of PCSK9 rs11206510 polymorphism affects the warfarin maintenance doses (P ˃ 0.0001).

Indexed as

cardiovascular diseaseCDKN2ACXCL1PCSK9warfarinWDR12

Identifiers

PMID33488114
PMCPMC7814275
OpenAlexW3119816479

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.